This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing the use of PLUVICTO to treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies.

Ticker(s): NVS

Who's the expert?

Institution: Methodist Cancer Center

  • Radiation oncologist at Methodist Estabrook Cancer Center and Methodist Jennie Edmundson Cancer Center
  • Clinical experience using Pylarify among 90 patients
  • Believes his role as a physician is to inform, educate and explain and takes into account his patients’ value systems, social situations, overall health and expectations.

Interview Goal
To better understand the use of Pluvicto as a treatment for MCRPC and see how it compares alongside other treatments in the field.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.